Alterations of hippocampal glucose metabolism by even versus uneven medium chain triglycerides

Journal of Cerebral Blood Flow and Metabolism

Volumn 34, Issue 1, 2014, Pages 153-160

  McDonald, Tanya S ^a   Tan, Kah Ni ^a   Hodson, Mark P ^a   Borges, Karin ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

epilepsy; metabolomics; mitochondria; pentose phosphate pathway; seizure; tricarboxylic acid cycle

Indexed keywords

3 HYDROXYBUTYRIC ACID; 6 PHOSPHOFRUCTOKINASE; DIHYDROXYACETONE PHOSPHATE; FRUCTOSE 6 PHOSPHATE; GLUCOSE; GLUCOSE 6 PHOSPHATE; LACTIC ACID; MEDIUM CHAIN TRIACYLGLYCEROL; OCTANOIC ACID; PHOSPHOENOLPYRUVATE; TRIHEPTANOIN; TRIOCTANOIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BENIGN CHILDHOOD EPILEPSY; BRAIN METABOLISM; CITRIC ACID CYCLE; CONTROLLED STUDY; ENZYMATIC ASSAY; ENZYME ANALYSIS; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HIPPOCAMPUS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLITE; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; SEIZURE;

EID: 84891837395     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.184     Document Type: Article

References (40)

1. Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol 2008; 7: 500-506.
2. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009; 6: 31-55.
3. Roe CR, Mochel F. Anaplerotic diet therapy in inherited metabolic disease. J Inherit Metab Dis 2006; 29: 332-340.
4. Willis S, Stoll J, Sweetman L, Borges K. Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models. Neurobiol Dis 2010; 40: 565-572.
5. Kim TH, Borges K, Petrou S, Reid CA. Triheptanoin reduces seizure susceptibility in a syndrome-specific mouse model of generalized epilepsy. Epilepsy Res 2013; 103: 101-105.
6. Thomas NK, Willis S, Sweetman L, Borges K. Triheptanoin in acute mouse seizure models. Epilepsy Res 2012; 99: 312-317.
7. Aso E, Semakova J, Joda L, Semak V, Halbaut L, Calpena A et al. Triheptanoin supplementation to ketogenic diet curbs cognitive impairment in APP/PS1 mice used as a model of familial Alzheimer's disease. Curr Alzheimer Res 2013; 10: 290-297.
8. Kuge Y, Yajima K, Kawashima H, Yamazaki H, Hashimoto N, Miyake Y. Brain uptake and metabolism of [1-11C] octanoate in rats: pharmacokinetic basis for its application as a radiopharmaceutical for studying brain fatty acid metabolism. Ann Nucl Med 1995; 9: 137-142.
9. Ebert D, Haller RG, Walton ME. Energy Contribution of Octanoate to Intact Rat Brain Metabolism Measured by 13C Nuclear Magnetic Resonance Spectroscopy. J Neurosci 2003; 23: 5928-5935.
10. Cremer JE, Teal HM, Heath DF, Cavanagh JB. The influence of portocaval anastomosis on the metabolism of labeled octanoate, butyrate and leucine in rat brain. J Neurochem 1977; 28: 215-222.
11. Edmond J, Robbins R, Bergstrom J, Cole R, De Vellis J. Capacity for substrate utilization in oxidative metabolism by neurons, astrocytes, and oligodendrocytes from developing brain in primary culture. J Neurosci Res 1987; 18: 551-561.
12. Wlaź P, Soca"a K, Nieoczym D, Łuszczki JJ, Zarnowska I, Zarnowski T et al. Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice. Neuropharmacology 2012; 62: 1882-1889.
13. Roe CR, Sweetman L, Roe DS, David F, Brunengraber H. Treatment of cardio-myopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 2002; 110: 259-269.
14. Brunengraber H, Roe CR. Anaplerotic molecules: current and future. J Inherit Metab Dis. 2006; 29: 327-331.
15. Borges K, Gearing M, McDermott DL, Smith AB, Almonte AG, Wainer BH et al. Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model. Exp Neurol 2003; 182: 21-34.
16. Kharatishvili I, Shan Z, She D, Foong S, Kurniawan N, Reutens D. MRI changes and complement activation correlate with epileptogenicity in a mouse model of temporal lobe epilepsy. Brain Struct Funct 2013. doi:10.1007/s00429- 013-0528-4 (e-pub ahead of print).
17. Le Belle JE, Harris NG, Williams SR, Bhakoo KK. A comparison of cell and tissue extraction techniques using high-resolution 1H-NMR spectroscopy. NMR Biomed 2002; 15: 37-44.
18. Bough KJ, Wetherington J, Hassel B, Pare JF, Gawryluk JW, Greene JG et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 2006; 60: 223-235.
19. Smeland OB, Hadera MG, McDonald TS, Sonnewald U, Borges K. Brain mito-chondrial metabolic dysfunction and glutamate level reduction in the pilocarpine model of temporal lobe epilepsy in mice. J Cereb Blood Flow Metab 2013; 33: 1090-1097.
20. Luo B, Groenke K, Takors R, Wandrey C, Oldiges M. Simultaneous determination of multiple intracellular metabolites in glycolysis, pentose phosphate pathway and tricarboxylic acid cycle by liquid chromatography-mass spectrometry. J Chroma-togr A 2007; 1147: 153-164.
21. Sangster T, Major H, Plumb R, Wilson AJ, Wilson ID. A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabo-nomic analysis. Analyst 2006; 131: 1075-1078.
22. Hodson MP, Dear GJ, Griffin JL, Haselden JN. An approach for the development and selection of chromatographic methods for high-throughput metabolomic screening of urine by ultra pressure LC-ESI-ToF-MS. Metabolomics 2009; 5: 166-182.
23. Randle PJ, Newsholme EA, Garland PB. Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 1964; 93: 652-665.
24. Décombaz J, Arnaud MJ, Milon H, Moesch H, Philippossian G, Thélin AL et al. Energy metabolism of medium-chain triglycerides versus carbohydrates during exercise. Eur J Appl Physiol 1983; 52: 9-14.
25. Marin-Valencia I, Good LB, Ma Q, Malloy CR, Pascual JM. Heptanoate as a neural fuel: energetic and neurotransmitter precursors in normal and glucose transporter I-deficient (G1D) brain. J Cereb Blood Flow Metab 2013; 33: 175-182.
26. Bak LK, Schousboe A, Waagepetersen HS. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem 2006; 98: 641-653.
27. Newsholme EA, Randle PJ, Manchester KL. Inhibition of the phosphofructokinase reaction in perfused rat heart by respiration of ketone bodies, fatty acids and pyruvate. Nature 1962; 193: 270-271.
28. Parmeggiani A, Bowman RH. Regulation of phosphofructokinase activity by citrate in normal and diabetic muscle. Biochem Biophys Res Commun 1963; 12: 268-273.
29. Garland PB, Randle PJ, Newsholme EA. Citrate as an intermediary in the inhibition of phosphofructokinase in rat heart muscle by fatty acids, ketone bodies, pyr-uvate, diabetes and starvation. Nature 1963; 200: 169-170.
30. Nishimura M, Uyeda K. Purification and characterization of a novel xylulose 5-phosphate-activated protein phosphatase catalyzing dephosphorylation of fructose-6-phosphate, 2-kinase: fructose-2, 6-bisphosphatase. J Biol Chem 1995; 270: 26341-26346.
31. Kabashima T, Kawaguchi T, Wadzinski BE, Uyeda K. Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver. Proc Natl Acad Sci USA 2003; 100: 5107-5112.
32. Petitet S, Morand C, Besson C, Rémésy C, Demigné C. Effects of propionate on rat hepatocyte metabolism. J Nutr Biochem 1998; 9: 652-658.
33. Stabile LP, Klautky SA, Minor SM, Salati LM. Polyunsaturated fatty acids inhibit the expression of the glucose-6-phosphate dehydrogenase gene in primary rat hepatocytes by a nuclear posttranscriptional mechanism. J Lipid Res 1998; 39: 1951-1963.
34. Salati LM, Amir-Ahmady B. Dietary regulation of expression of glucose-6-phos-phate dehydrogenase. Annu Rev Nutr 2001; 21: 121-140.
35. Nakatsu K, Mansour TE. Effect of perfusion with different substrates and with isoproterenol on phosphofructokinase activity in the isolated guinea pig heart. Mol Pharmacol 1973; 9: 405-413.
36. Gasior M, Yankura J, Hartman AL, French A, Rogawski MA. Anticonvulsant and proconvulsant actions of 2-deoxy-D-glucose. Epilepsia 2010; 51: 1385-1394.
37. Lian X-Y, Khan FA, Stringer JL. Fructose-1, 6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats. J Neurosci 2007; 27: 12007-12011.
38. Stafstrom CE, Ockuly JC, Murphree L, Valley MT, Roopra A, Sutula TP. Antic-onvulsant and antiepileptic actions of 2, deoxy-D-glucose in epilepsy models. Ann Neurol 2009; 65: 435-447.
39. Samala R, Klein J, Borges K. The ketogenic diet changes metabolite levels in hippocampal extracellular fluid. Neurochem Int 2011; 58: 5-8.
40. Stringer JL, Xu K. Possible mechanisms for the anticonvulsant activity of fructose-1, 6-diphosphate. Epilepsia 2008; 49: 101-103.